Ferroquine (SSR97193) + Placebo + artesunate
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Plasmodium Falciparum Infection
Conditions
Plasmodium Falciparum Infection
Trial Timeline
Oct 1, 2009 → Nov 1, 2010
NCT ID
NCT00988507About Ferroquine (SSR97193) + Placebo + artesunate
Ferroquine (SSR97193) + Placebo + artesunate is a phase 2 stage product being developed by Sanofi for Plasmodium Falciparum Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT00988507. Target conditions include Plasmodium Falciparum Infection.
What happened to similar drugs?
0 of 2 similar drugs in Plasmodium Falciparum Infection were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00988507 | Phase 2 | Terminated |
Competing Products
13 competing products in Plasmodium Falciparum Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 40 |
| artemether:lumefantrine (2.5 mg:30 mg) | Novartis | Phase 2/3 | 30 |
| INE963 | Novartis | Phase 2 | 35 |
| KAE609 + Piperaquine Phosphate | Novartis | Phase 1 | 21 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 35 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 35 |
| Artemether-lumefantrine | Novartis | Phase 3 | 40 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 42 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 35 |
| Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine | Pfizer | Phase 2/3 | 38 |
| Ferroquine SSR97193 + Artefenomel | Sanofi | Phase 2 | 27 |
| Artefenomel (OZ439) + Ferroquine (SSR97193) | Sanofi | Phase 2 | 35 |
| Meplazumab for Injection + Sterile normal saline (0.9%) | Pacific Biosciences | Phase 1 | 11 |